Efficacy and safety of FOLFIRI/aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen.

Nieves Martínez-Lago Soledad Cameselle GarcíaBeatriz Alonso de CastroMartín I Gómez-Randulfe RodríguezMarta Carmona CamposPaula González VillarroelMercedes Salgado FernándezJuan C De la Cámara GómezCarlos Romero ReinosoAntía Cousillas CastiñeirasJosé Carlos Méndez MéndezYolanda Vidal InsuaAna Fernández-Montes

Published in: PloS one (2022)

FA combination is effective in patients ≥70 years. The occurrence of HT is predictive of efficacy. Close monitoring of toxicity and initial dose adjustment is recommended.

Keyphrases

metastatic colorectal cancer
end stage renal disease
newly diagnosed
ejection fraction
risk assessment
peritoneal dialysis
oxidative stress
wild type